Suppliers / Lundbeck Pharmaceuticals Italy

Lundbeck Pharmaceuticals Italy

Italy Updated 9 July 2026

Lundbeck Pharmaceuticals Italy is a contract manufacturer based in Italy. It holds 8 active US drug master files and one valid CEP across a filed portfolio of 8 molecules. Its most recent recorded inspection, by US FDA, closed on 25 March 2022 as VAI.

8
active US DMFs
1
valid CEPs
2
registered plants 1 with an FDA FEI number
1
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
5 of 5 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 25 March 2022 VAI US FDA
  • 12 May 2017 VAI US FDA
  • 17 April 2015 NAI US FDA
  • 28 September 2012 NAI US FDA
  • 13 March 2009 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Padova, Italy Not on file
Italy, Italy 3002808449

What they file, and where

Molecule Regulators Docs
Trimipramine EDQM, US FDA 2
(21R)-Argatroban US FDA 1
Clomipramine US FDA 1
Dapsone US FDA 1
Desipramine US FDA 1
Diazoxide US FDA 1
Imipramine US FDA 1
Metoclopramide US FDA 1

Also appears on these molecule pages

Citalopram contract manufacturing Escitalopram contract manufacturing Metoclopramide contract manufacturing Naltrexone contract manufacturing

Filings and GMP by regulator

Regulator Filings GMP certificates
MPA (SE) 1 None

Comparing suppliers?

Choose your molecules and target markets. Lundbeck Pharmaceuticals Italy comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 25 March 2022.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability